MX2016003855A - Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso. - Google Patents

Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso.

Info

Publication number
MX2016003855A
MX2016003855A MX2016003855A MX2016003855A MX2016003855A MX 2016003855 A MX2016003855 A MX 2016003855A MX 2016003855 A MX2016003855 A MX 2016003855A MX 2016003855 A MX2016003855 A MX 2016003855A MX 2016003855 A MX2016003855 A MX 2016003855A
Authority
MX
Mexico
Prior art keywords
vaccine composition
methods
pcv2b
pcv2b divergent
divergent vaccine
Prior art date
Application number
MX2016003855A
Other languages
English (en)
Inventor
Gregory Paul Nitzel
David Ewell Slade
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2016003855A publication Critical patent/MX2016003855A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/10044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10071—Demonstrated in vivo effect

Abstract

La presente invención proporciona una composición de vacuna para proteger a los cerdos frente al PCV2, incluyendo una cepa de circovirus porcino tipo 2b (PCV2b) divergente altamente virulenta, incluyendo la composición un polipéptido de ORF2 de PCV2b divergente, en donde el polipéptido de ORF2 comprende leucina (L) en la posición 89, treonina (T) en la posición 90 y asparagina (N) en la posición 134, de acuerdo con la numeración de SEQ ID NO: 1 en el presente documento.
MX2016003855A 2013-09-25 2014-09-24 Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso. MX2016003855A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361882289P 2013-09-25 2013-09-25
PCT/US2014/057190 WO2015048115A1 (en) 2013-09-25 2014-09-24 Pcv2b divergent vaccine composition and methods of use

Publications (1)

Publication Number Publication Date
MX2016003855A true MX2016003855A (es) 2016-08-04

Family

ID=51688446

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003855A MX2016003855A (es) 2013-09-25 2014-09-24 Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso.

Country Status (12)

Country Link
US (1) US9987348B2 (es)
EP (2) EP4091629A1 (es)
JP (2) JP6821429B2 (es)
KR (2) KR20160046879A (es)
CN (1) CN105579060B (es)
BR (1) BR112016006192A2 (es)
CA (1) CA2925281C (es)
HK (1) HK1225645A1 (es)
MX (1) MX2016003855A (es)
PH (1) PH12016500473A1 (es)
RU (1) RU2662685C2 (es)
WO (1) WO2015048115A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014182872A1 (en) 2013-05-08 2014-11-13 Protatek International, Inc. Vaccine for pcv2 and mycoplasma
KR20160046879A (ko) * 2013-09-25 2016-04-29 조에티스 서비시즈 엘엘씨 Pcv2b 분지형 백신 조성물 및 사용 방법
CN109195623A (zh) * 2016-03-07 2019-01-11 弗吉尼亚科技知识产权有限公司 嵌合型猪圆环病毒2型(pcv2)疫苗
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CN106754980A (zh) * 2016-12-29 2017-05-31 福州大学 Pcv2型衣壳蛋白基因、表达菌株及可溶性表达方法
MX2020003626A (es) * 2017-10-17 2021-08-12 Intervet Int Bv Expresión recombinante de la proteína orf2 de pcv2b en células de insecto.
JP2021527073A (ja) * 2018-06-11 2021-10-11 セヴァ サンテ アニマレＣｅｖａ Ｓａｎｔｅ Ａｎｉｍａｌｅ ブタサーコウイルスに対するワクチン接種
CN110606873B (zh) * 2019-09-09 2021-05-04 武汉科前生物股份有限公司 猪圆环病毒2d型与3型Cap蛋白二联亚单位疫苗及其制备方法与应用
KR20230073462A (ko) * 2021-11-19 2023-05-26 주식회사 이노백 신규한 재조합 돼지 써코바이러스 2형 단백질 및 이의 용도
CN115960259B (zh) * 2022-10-07 2023-11-24 浙江大学 一种模块化组装双组分纳米颗粒制备方法及其应用
CN117100851A (zh) * 2023-10-23 2023-11-24 成都依思康生物科技有限公司 一种佐剂、疫苗组合物及其制备方法和应用

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262533A (en) 1939-12-09 1941-11-11 William D Hedge Water-cooled grate
FR964808A (es) 1941-03-20 1950-08-25
FR2422956A1 (fr) 1978-04-13 1979-11-09 Pasteur Institut Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede
FR2518755B1 (fr) 1981-12-23 1986-04-11 Pasteur Institut Sonde contenant un acide nucleique modifie et reconnaissable par des anticorps specifiques et utilisation de cette sonde pour detecter et caracteriser une sequence d'adn homologue
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4567043A (en) 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5545412A (en) 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US5106733A (en) 1987-06-25 1992-04-21 Immunex Corporation Bovine granulocyte-macrophage colony stimulating factor
SU1538305A1 (ru) 1987-07-21 1994-12-15 Всесоюзный государственный научно-контрольный институт ветеринарных препаратов Госагропрома СССР Ассоциированная вакцина против лептоспироза и парвовирусной инфекции свиней
US5238662A (en) 1987-07-31 1993-08-24 Chevron Research Company Processes for recovering precious metals
US5069901A (en) 1988-02-03 1991-12-03 Jones Elaine V Preparation of a recombinant subunit vaccine against pseudorabies infection
DK0454735T3 (da) 1989-01-23 1996-10-07 Auspharm Int Ltd Vaccine sammensætning
US5811103A (en) 1989-03-19 1998-09-22 Akzo Nobel N.V. Hog cholera virus vaccine and diagnostic
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2200016T3 (es) 1989-03-21 2004-03-01 Vical Incorporated Expresion de secuencias polinucleotidicas exogenas en un vertebrado.
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
ATE160699T1 (de) 1990-05-29 1997-12-15 American Cyanamid Co Impfstoff gegen die pneumonie bei schweinen und verfahren zu seiner herstellung
US5147966A (en) 1990-07-31 1992-09-15 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polyimide molding powder, coating, adhesive and matrix resin
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
WO1992005255A1 (en) 1990-09-13 1992-04-02 Commonwealth Scientific And Industrial Research Organisation Ovine cytokine genes
GB9023111D0 (en) 1990-10-24 1990-12-05 Wellcome Found Expression system
WO1992007934A1 (en) 1990-11-01 1992-05-14 Iowa State University Research Foundation, Inc. Bacterial attenuation method and vaccine
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
ES2026827A6 (es) 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino.
US5580557A (en) 1991-10-09 1996-12-03 Iowa State University Research Foundation, Inc. Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
US6033904A (en) 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
EP0651656A1 (en) 1992-07-08 1995-05-10 Schering Corporation Use of gm-csf as a vaccine adjuvant
KR100374295B1 (ko) 1993-02-08 2003-12-24 바이엘 코포레이션 돼지생식및호흡증후군바이러스의생육방법과백신에서그의용도
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
EP0698245A1 (en) 1993-05-14 1996-02-28 Mds Health Group Limited Electronic worksheet system for microbiology testing and reporting
WO1994027435A1 (en) 1993-06-01 1994-12-08 Life Technologies, Inc. Genetic immunization with cationic lipids
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
CA2190121A1 (en) 1994-03-15 1995-09-21 Edith Mathiowitz Polymeric gene delivery system
WO1995030018A2 (en) 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
AU711350B2 (en) 1994-05-10 1999-10-14 Zoetis Services Llc Improved modified live BRSV vaccine
DK53595A (da) 1994-05-13 1995-11-14 Iberica Cyanamid Rekombinante PRRSV-proteiner, diagnostiske kits og vaccine indeholdende sådanne rekombinante PRRSV-proteiner
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
US6043232A (en) 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
US5885823A (en) 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
EP0832242A1 (en) 1995-06-07 1998-04-01 Aesculaap B.V. Neutralizing conformational epitopes of chicken anemia virus
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5795872A (en) 1995-09-19 1998-08-18 Pharmadigm, Inc. DNA construct for immunization
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
DE69704011T2 (de) 1996-10-09 2001-06-07 Akzo Nobel Nv Europäische Vakzinstämme des Fortplanzungs-Atmungs-Syndromsvirus des Sweins (PRRSV)
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
WO1998040499A1 (en) 1997-03-10 1998-09-17 Heather Lynn Davis Gene delivery to mucosal epithelium for immunization or therapeutic purposes
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US7192594B2 (en) 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2769321B1 (fr) 1997-10-03 2001-10-26 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostics
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
FR2769322B1 (fr) 1997-10-03 2002-03-08 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostic
US7211379B2 (en) 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6165493A (en) 1997-10-22 2000-12-26 New York Blood Center, Inc. "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
AU1535299A (en) 1997-11-26 1999-06-15 Iowa State University Research Foundation Inc. Recombinant (mycoplasma hyopneumoniae) vaccine
US20040062775A1 (en) 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
PT2363488E (pt) 1997-12-11 2015-01-13 Univ Belfast Síndrome multi-sistémica do definhamento pós-desmame de porcos
WO1999045956A1 (en) 1998-03-13 1999-09-16 University Of Georgia Research Foundation, Inc. Vaccines against circovirus infections
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
AU1131200A (en) 1998-10-23 2000-05-15 Heska Corporation Cationic lipid-mediated enhancement of nucleic acid immunization of cats
NZ501264A (en) 1998-12-22 2001-09-28 Pfizer Prod Inc Polynucleotide DNA sequence encoding an infectious RNA molecule encoding a North American PRRS
FR2789695B1 (fr) 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6179461B1 (en) 1999-09-03 2001-01-30 Davis-Standard Corporation Extruder screw
US6139179A (en) 1999-09-03 2000-10-31 Davis-Standard Corporation Extruder screw having multi-channeled barrier section
WO2001017556A1 (fr) 1999-09-07 2001-03-15 Shionogi & Co., Ltd. Préparations vaccinales administrables par les muqueuses
EP1290016A2 (en) 2000-06-15 2003-03-12 Purdue Research Foundation Vaccine for congenital tremors in pigs
DE10044648A1 (de) 2000-09-08 2002-03-21 Aventis Behring Gmbh Verfahren zur Vermehrung oder zur Entfernung von Cirocoviren aus biologischem Material
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
EP1379671B1 (en) 2001-03-27 2009-05-06 University of Saskatchewan Methods to culture circovirus
AUPR567401A0 (en) 2001-06-14 2001-07-12 University Of Melbourne, The Circovirus vaccines
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US20030215455A1 (en) 2002-05-14 2003-11-20 Bailey Reynolds Vaccine stabilizer and method of use
AU2003280431A1 (en) 2002-06-28 2004-01-19 Department Of Agriculture For And On Behalf Of The State Of New South Wales Immunogenic mycoplasma hyopneumoniae polypeptides
AU2004260657B2 (en) 2003-07-25 2012-06-07 Boehringer Ingelheim Animal Health USA Inc. Lawsonia intracellularis of European origin and vaccines, diagnostic agents and methods of use thereof
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
KR20070096019A (ko) 2005-01-13 2007-10-01 베링거잉겔하임베트메디카게엠베하 향상된 ｐｒｒｓ 백신
ES2589928T3 (es) 2005-04-13 2016-11-17 Merial, Inc. Procedimiento para la producción de circovirus porcino
KR101347503B1 (ko) * 2005-09-09 2014-01-02 인터벳 인터내셔널 비.브이. Ｐｃｖ-2 백신
EP3320919B1 (en) * 2005-12-29 2020-05-27 Boehringer Ingelheim Animal Health USA Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
DK2371385T3 (en) 2005-12-29 2015-11-30 Boehringer Ingelheim Vetmed Use of a PV2 immunogen composition for reduction of clinical symptoms in pigs
AU2007333857B2 (en) * 2006-12-15 2014-05-15 Boehringer Ingelheim Animal Health USA Inc. Treatment of pigs with PCV2 antigen
US20090017064A1 (en) 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US20090162398A1 (en) * 2007-12-21 2009-06-25 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
EA201100862A1 (ru) 2008-11-28 2012-01-30 Сева Санте Анималь Новый изолят свиного цирковируса типа 2b и его применения
ES2773722T3 (es) * 2010-03-16 2020-07-14 Virginia Tech Intellectual Properties Inc Vacuna de circovirus porcino quimérico atenuado vivo
CN102296089B (zh) * 2011-04-20 2013-09-11 中国兽医药品监察所 高效制备猪圆环病毒2型空衣壳粒子的方法
BR112013030321A2 (pt) * 2011-05-27 2017-07-11 Sinovet Beijing Biotechnology Co Ltd composição de vacina, método para preparar a composição de vacina, uso da composição de vacina, método para imunizar um porco, cepa de vacina contra csfv e uso de uma célula no cultivo de uma cepa de vacina contra csfv.
CN103122352B (zh) * 2012-09-27 2015-02-11 华中农业大学 一种猪圆环病毒2型重组杆状病毒及制备方法和应用
CN105451765A (zh) 2013-08-23 2016-03-30 勃林格殷格翰动物保健公司 猪圆环病毒2型(pcv2)亚单位疫苗
KR20160046879A (ko) * 2013-09-25 2016-04-29 조에티스 서비시즈 엘엘씨 Pcv2b 분지형 백신 조성물 및 사용 방법

Also Published As

Publication number Publication date
CA2925281C (en) 2022-05-03
US20160220658A1 (en) 2016-08-04
CN105579060A (zh) 2016-05-11
RU2016110430A (ru) 2017-10-30
JP6821429B2 (ja) 2021-01-27
JP2019206541A (ja) 2019-12-05
RU2662685C2 (ru) 2018-07-26
CN105579060B (zh) 2021-03-16
PH12016500473B1 (en) 2016-05-16
CA2925281A1 (en) 2015-04-02
HK1225645A1 (zh) 2017-09-15
US9987348B2 (en) 2018-06-05
EP3049106A1 (en) 2016-08-03
EP4091629A1 (en) 2022-11-23
BR112016006192A2 (pt) 2017-09-26
KR20180041245A (ko) 2018-04-23
PH12016500473A1 (en) 2016-05-16
KR102319843B1 (ko) 2021-10-29
KR20160046879A (ko) 2016-04-29
WO2015048115A1 (en) 2015-04-02
JP2016531854A (ja) 2016-10-13

Similar Documents

Publication Publication Date Title
PH12016500473A1 (en) Pcv2b divergent vaccine composition and methods of use
EP4233898A3 (en) Influenza mrna vaccines
MX2017011974A (es) Estabilizacion del 1-cloro-3,3,3-trifluoropropeno.
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX2015000338A (es) Novedosa cepa de lactobacillus crispatus.
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
CL2019001200A1 (es) Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio reproductivo porcino y métodos de producción de esta.
CL2016000300A1 (es) Métodos terapéuticos
BR112018010679A8 (pt) métodos para tratar, prevenir e diagnosticar a infecção por vírus da diarréia epidêmica porcina
CO2019010062A2 (es) Novedoso bacteriófago clo-pep-2 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
WO2016100615A3 (en) Methods and composition for neutralization of influenza
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
MX2017016401A (es) Composiciones inmunogenas.
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
MX2019007574A (es) Metodos de tratamiento de sindrome de intestino irritable con formulaciones modificadas o de liberacion retardada de linaclotida.
PH12017501943B1 (en) Influenza virus neutralizing peptidomimetic compounds
TW201613952A (en) Cdca1-derived peptide and vaccine containing same
CU20210061A7 (es) Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer
PH12016501715A1 (en) Beta hairpin peptides having antiviral properties against dengue virus

Legal Events

Date Code Title Description
FG Grant or registration